Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma
1. Disease-free survival in the placebo group was 50.7 months and was never reached in the intervention group; however, there ...
1. Disease-free survival in the placebo group was 50.7 months and was never reached in the intervention group; however, there ...
Patients receiving adjuvant pembrolizumab after nephrectomy for renal-cell carcinoma showed significantly improved disease-free survival compared to patients receiving placebo treatment. ...
1. Patients receiving adjuvant pembrolizumab after nephrectomy for renal-cell carcinoma showed significantly improved disease-free survival compared to patients receiving placebo ...
1. Regional variation in cumulative risk of an individual having a chest or abdominal CT in the United States was ...
Originally published by Harvard Health. What Is It? A nephrectomy is the surgical removal of a kidney, the organ that ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.